CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱^®) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative (HER2-) breast cancer (BC) was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University (Presentation # LBA23, Proffered paper session 1: Breast cancer, metastatic). Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration (NMPA) and was included in the priority review and approval process.